Biophan Scientist Selected to Present Company Research to Annual Meeting of the Radiological Society of North America.

ROCHESTER, N.Y. -- Senior Scientist Robert W. Gray to Report on Biophan Innovations in Design of Surgically Implanted Devices to Increase MRI Safety

Biophan Technologies, Inc. (OTC BB:BIPH), a developer of next-generation biomedical technology, has announced that Biophan will present recent research results at the Radiological Society of North America's (RSNA) annual scientific assembly and meeting. The announcement was made by Michael Weiner, Biophan CEO.

The Radiological Society of North America is one of the world's leading associations of radiologists and related science and health care professionals. Biophan Senior Scientist Robert W. Gray will make the presentation at RSNA's 90th Scientific Assembly and Annual Meeting, in Chicago, IL, to be held Nov. 28 - Dec. 3.

Dr. Frank G. Shellock, a member of Biophan's Scientific Advisory Board and a widely recognized authority on MRI safety, co-authored the presentation entitled "Design Changes to Implanted Device Leads Substantially Reduce MRI Related Heating." W.T. Bibens, a research manager at Biophan (formerly with Johnson & Johnson and Allied Signal), is also a co-author.

In his presentation, Mr. Gray will describe Biophan's research into design modifications to leads or wires for implanted medical devices undergoing magnetic resonance imaging (MRI). Biophan's research has demonstrated important safety implications for MRI-related heating of device leads, and can contribute to the substantial reduction in the risks associated with MRI imaging for patients with implanted devices.

"The presentation of Biophan's findings on MRI Safety at the RSNA Scientific Assembly is an important milestone for us, and we are pleased to be selected," stated Mr. Weiner. "Dr. Shellock's collaboration as co-author of this presentation makes the occasion much more special for us. Dr. Shellock is well-known throughout the world as one of the leading experts on MRI Safety."

Mr. Gray has been a research scientist at Biophan since 2000. He is co-inventor of several patents relating to MRI technology and safety, and holds master's degrees in theoretical and experimental physics from SUNY Binghamton and the University of Rochester. He spent 10 years at IBM, and has published scientific papers in peer-reviewed physics and cartography journals.

Dr. Shellock, a world-renown authority on MRI safety, is Adjunct Clinical Professor of Radiology and Medicine at the Keck School of Medicine, University of Southern California and the Founder of the Institute for Magnetic Resonance Safety, Education, and Research (www.IMRSER.org). Dr. Shellock created the internationally popular web site, www.MRIsafety.com, and is author of five medical textbooks, over 60 book chapters, and more than 190 peer-reviewed articles.

About Radiological Society of North America

The mission of the Radiological Society of North America is to promote and develop the highest standards of radiology and related sciences through education and research. The Society seeks to provide radiologists and allied health scientists with educational programs and materials of the highest quality, and to constantly improve the content and value of these educational activities. The Society seeks to promote research in all aspects of radiology and related sciences, including basic clinical research in the promotion of quality healthcare. The Society seeks to foster closer fellowship among all radiologists and greater cooperation among radiologists and members of other branches of medicine and allied healthcare professionals.

About Biophan Technologies

Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers, and interventional surgical devices such as catheters and guidewires, as well as stents and other implants that can be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan product lines include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors have a total of 101 U.S. patents issued, pending, or allowed. This total includes 22 issued U.S. patents, 11 recently-allowed applications that will issue as patents in the near future, and 68 pending applications at various stages of examination at the U.S. Patent and Trademark Office, in areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE:BSX) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit http://www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors including, but not limited to: the development of Biophan's MRI technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the acceptance by the market of Biophan's products; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.